AZD 9898

Drug Profile

AZD 9898

Alternative Names: AZD9898

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orexo
  • Developer AstraZeneca
  • Class Anti-inflammatories; Antiasthmatics; Small molecules
  • Mechanism of Action Leukotriene-C4 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 12 Feb 2018 Discontinued - Phase-I for Asthma in United Kingdom (PO) (AstraZeneca pipeline, February 2018)
  • 17 Jan 2018 AstraZeneca terminates a phase I trial in Asthma in United Kingdom after an interim review (NCT03140072)
  • 13 Sep 2017 Pharmacodynamic results from preclinical studies in Asthma presented at the 27th Annual Congress of the European Respiratory Society (ERS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top